EP Patent

EP2861254A2 — Pharmaceutical compositions for combination therapy

Assigned to Acesion Pharma ApS · Expires 2015-04-22 · 11y expired

What this patent protects

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective amount of a sodium channel inhibitor, in a combination with a small-conductance calcium-activated potassium (SK) channel inhibitor, for the treatment of cardiac arrhythmias.

USPTO Abstract

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective amount of a sodium channel inhibitor, in a combination with a small-conductance calcium-activated potassium (SK) channel inhibitor, for the treatment of cardiac arrhythmias.

Drugs covered by this patent

Patent Metadata

Patent number
EP2861254A2
Jurisdiction
EP
Classification
Expires
2015-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Acesion Pharma ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.